Clinical performance of the novel Genmark DX eplex blood culture ID Gram-positive panel

Karen C. Carroll, Jennifer L. Reid, Adam Thornberg, Natalie N. Whitfield, Deirdre Trainor, Shawna Lewis, Teresa Wakefield, Thomas E. Davis, Keisha G. Church, Linoj Samuel, Ray Mills, Patricia Jim, Stephen Young, Frederick S. Nolte

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Rapid identification from positive blood cultures is standard of care (SOC) in many clinical microbiology laboratories. The GenMark Dx ePlex Blood Culture Identification Gram-Positive (BCID-GP) Panel is a multiplex nucleic acid amplification assay based on competitive DNA hybridization and electrochemical detection using eSensor technology. This multicenter study compared the investigational-use-only (IUO) BCID-GP Panel to other methods of identification of 20 Gram-positive bacteria, four antimicrobial resistance genes, and both Pan Candida and Pan Gram-Negative targets that are unique to the BCID-GP Panel. Ten microbiology laboratories throughout the United States collected residual, deidentified positive blood culture samples for analysis. Five laboratories tested both clinical and contrived samples with the BCID-GP Panel. Comparator identification methods included each laboratory's SOC, which included matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and automated identification systems as well as targeted PCR/analytically validated real-time PCR (qPCR) with bidirectional sequencing. A total of 2,342 evaluable samples (1,777 clinical and 565 contrived) were tested with the BCID-GP Panel. The overall sample accuracy for on-panel organisms was 89% before resolution of discordant results. For pathogenic Gram-positive targets (Bacillus cereus group, Enterococcus spp., Enterococcus faecalis, Enterococcus faecium, Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Listeria spp., Listeria monocytogenes, Streptococcus spp., Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus pneumoniae, and Streptococcus pyogenes), positive percent agreement (PPA) and negative percent agreement (NPA) ranged from 93.1% to 100% and 98.8% to 100%, respectively. For contamination rule-out targets (Bacillus subtilis group, Corynebacterium, Cutibacterium acnes, Lactobacillus, and Micrococcus), PPA and NPA ranged from 84.5% to 100% and 99.9% to 100%, respectively. Positive percent agreement and NPA for the Pan Candida and Pan Gram-Negative targets were 92.4% and 95.7% for the former and 99.9% and 99.6% for the latter. The PPAs for resistance markers were as follows: mecA, 97.2%; mecC, 100%; vanA, 96.8%; and vanB, 100%. Negative percent agreement ranged from 96.6% to 100%. In conclusion, the ePlex BCID-GP Panel compares favorably to SOC and targeted molecular methods for the identification of 20 Gram-positive pathogens and four antimicrobial resistance genes in positive blood culture bottles. This panel detects a broad range of pathogens and mixed infections with yeast and Gram-negative organisms from the same positive blood culture bottle.

Original languageEnglish (US)
Article numbere01730-19
JournalJournal of clinical microbiology
Volume58
Issue number4
DOIs
StatePublished - 2020

Keywords

  • Blood culture
  • ESensor technology
  • Gram-positive bacteria
  • Identification
  • Multiplex nucleic acid test
  • Resistance marker

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Clinical performance of the novel Genmark DX eplex blood culture ID Gram-positive panel'. Together they form a unique fingerprint.

  • Cite this

    Carroll, K. C., Reid, J. L., Thornberg, A., Whitfield, N. N., Trainor, D., Lewis, S., Wakefield, T., Davis, T. E., Church, K. G., Samuel, L., Mills, R., Jim, P., Young, S., & Nolte, F. S. (2020). Clinical performance of the novel Genmark DX eplex blood culture ID Gram-positive panel. Journal of clinical microbiology, 58(4), [e01730-19]. https://doi.org/10.1128/JCM.01730-19